General info: biotech/pharmaceutical
WORLD SALES THROUGH RETAIL PHARMACIES*
---------------------------------------------------------------------------
(Twelve months to April 2002)
NORTH AMERICA $145.4billion, up 16%
United States $138.9billion, up 16%
Canada $6.5billion, up 16%
EUROPE (leading 5) $54.7billion, up 10%
Germany $15.6billion, up 10%
France $13.8billion, up 7%
Italy $9.7billion, up 10%
United Kingdom $9.8billion, up 12%
Spain $5.8billion, up 11%
JAPAN (including hospitals) $46.8billion, up 5%
LATIN AMERICA (leading 3) $12.5billion, down 7%
Mexico $5.9billion, up 15%
Brazil $4.1billion, down 17%
Argentina $2.5billion, down 25%
AUSTRALIA/NEW ZEALAND $2.9billion, up 8%
Source: IMS HEALTH. Growth rates are calculated at a constant exchange rate, i.e. at the local currency level. The unique system in Japan reduces the importance of the pharmacy in the distribution chain - sales for Japan include hospital data. For the USA, retail, foodstore and mail order pharmacy channels are included. In other countries sales monitored are limited to retail pharmacies only.
COMPANY NEWS IN BRIEF FOR JUNE
-----------------------------------------------------------
BRISTOL-MYERS SQUIBB hired a new CFO, pledged to sort out its wholesaler inventory problems and hired Goldman Sachs to help boost its pipeline. It is still under scrutiny following the arrest of ex-IMCLONE CEO Sam Waksal and a congressional hearing into leaks about the FDA's rejection of Erbitux and insider trading. CHUGAI's shareholders approved ROCHE's acquisition of a 50.1% stake. PLIVA acquired SOBEL of the US, BARR certain assets of ENHANCE and SCHERING AG sold Asche to CHIESI. Schering and AVENTIS completed the sale of their crop science business to BAYER, with both using the funds to expand pharma operations. SERONO bid for GENSET, while BAXTER will acquire WYETH's ESI Lederle business.
RANBAXY acquired PROCTER & GAMBLE's German antihypertensive Veratide, while Schering AG licensed antithrombotic Refludan to PHARMION outside North America and returned the rights to DUSA's Levulan PDT. IMPAX signed an agreement with SCHERING-PLOUGH for OTC Claritin-D 12 Hour, but the two are still in litigation over a generic version, which Impax began an alliance for with Wyeth, as did CIMA for an OTC version of Claritin RediTabs. MOCHIDA licensed LUNDBECK's new antidepressant Cipralex for Japan. ABBOTT and CELERA formed an alliance for molecular diagnostics, while Roche licensed STRESSGEN's developmental HPV drug and expanded its antibody collaboration with GENMAB.
UCB and ELAN launched VERNALIS' migraine drug Frova in the US, and BOEHRINGER INGELHEIM and PFIZER launched COPD therapy Spiriva in its first markets, the Netherlands and Philippines. The FDA cleared Ritalin LA, from NOVARTIS, Elan and CELGENE, for ADHD, an injectable formulation of Pfizer's antipsychotic Geodon, and ANDRX's Altocor, a reformulation of MERCK & CO's statin Mevacor. The agency also said GLAXOSMITHKLINE could re-introduce IBS drug Lotronex, but rejected OGS' Gaucher treatment Vevesca and ASTRAZENECA's sNDA for Casodex in early prostate cancer. The EU approved Roche's Pegasys for hepatitis C and flu drug Tamiflu, and cleared SANOFI-SYNTHELABO and BMS' antihypertensive Aprovel/Karvea for diabetic renal disease. Australia granted the first approval for asthma antibody Xolair from Novartis, GENENTECH and TANOX.
Merck & Co strengthened the warnings for statin Zocor, while Vioxx was linked to the development of hypertension. Pfizer returned the rights to INDEVUS' anxiolytic pagoclone and CORVAS' stroke drug, and GSK will not advance IMMUNOGEN's cancer antibody cantuzumab. BAUSCH & LOMB lost a contact lens patent case against Novartis, but won the suit brought by ALLERGAN over generic Alphagan, for glaucoma. Pfizer lost a UK impotence patent: Viagra is still protected, but ELI LILLY and ICOS will be able to introduce Cialis. In the US, Pfizer sued DR REDDY'S and RANBAXY for infringing patents for Norvasc and Diflucan respectively. Two antitrust suits against AstraZeneca over Prilosec were dismissed, and an FDA panel said P&G should be allowed to sell an OTC version.
Genentech was ordered to pay City of Hope $500 million for breaching a royalty contract. Minnesota sued PHARMACIA for inflating the price of cancer drugs, 29 states sued BMS over its attempts to prevent generic Taxol, and GSK's tax bill is being investigated by the IRS. The SEC is looking into ALPHARMA's accounting, while Merck Medco's was queried and its IPO delayed. The US attorney is investigating Schering-Plough, which is streamlining its sales teams. BIOVAIL and Elan dissolved their agreement for generic Adalat CC to satisfy the FTC, and Elan announced a corporate governance plan. Celera is restructuring to focus on drug development, and ICN's controversial CEO Milan Panic retired. |
